Showing 4341-4350 of 5314 results for "".
- Celluma Light Therapy Headquarters Moves to Tustin, Californiahttps://practicaldermatology.com/news/celluma-light-therapy-headquarters-moves-to-tustin-calif/2461570/BioPhotas, Inc., the maker of the Celluma Series of light therapy devices, is moving its corporate headquarters and manufacturing operations from Anaheim to Tustin, Calif. The new headquarters boasts 25,000 square feet of office and warehouse space, facilitating continued gro
- DermTech Melanoma Test Recommended for Coverage by the Veterans Health Administrationhttps://practicaldermatology.com/news/dermtech-melanoma-test-recommended-for-coverage-by-the-veterans-health-administration/2461554/The U.S. General Services Administration has recommended DermTech‘s foundational assay included in the DermTech Melanoma Test (DMT) for coverage by the Veterans Health Administration (VHA), according to a company news release. This coverage recommendation makes the foundational as
- MTX Use May Up Risk for Three Types of Skin Cancerhttps://practicaldermatology.com/news/mtx-use-may-up-skin-cancer-risk/2461546/Methotrexate (MTX) may increase risk for three types of skin cancer, according to a new study out of University of Gothenburg. Patients receiving the drug include those with moderate to severe psoriasis; but in this particular patient group, a risk increase was only observed for basal c
- New Biomarkers May Help Advance Melanoma Detectionhttps://practicaldermatology.com/news/new-biomarkers-may-help-advance-melanoma-detection/2461539/New biomarkers to improve skin cancer detection and avoid delays in treatment are being developed by researchers at the University of South Australia. “Melanomas exhibit a wide range of sizes, shapes and growth, which can resemble numerous benign and other malignant skin lesions,&
- Daniel Hopkins Named New CEO at AlumierMDhttps://practicaldermatology.com/news/daniel-hopkins-named-new-ceo-at-alumiermd/2461537/Daniel Hopkins is AlumierMD’s new Chief Executive Officer. With more than a decade of experience in the aesthetic sector, Mr. Hopkins is prepared to take AlumierMD's commitment to the global aesthetic community through its next exciting phase of growth. Mr. Hopkins
- Mount Sinai Physician Promises $5 Million Bequest to Support the Kimberly and Eric J. Waldman Department of Dermatologyhttps://practicaldermatology.com/news/mount-sinai-physician-promises-5-million-bequest-to-support-the-kimberly-and-eric-j-waldman-department-of-dermatology/2461536/The Kimberly and Eric J. Waldman Department of Dermatology at the Icahn School of Medicine at Mount Sinai received a $5 million bequest promised by Kenneth L. Edelson, MD, Clinical Professor of Dermatology. This gift represents Dr. Edelson’s commitment to advancing dermatolo
- Phase 2 Data: Jeuveau “Extra-Strength” Dose Produces Lasting Resultshttps://practicaldermatology.com/news/phase-2-data-jeuveau-extra-strength-dose-produces-lasting-results/2461528/Evolus' Jeuveau Extra-Strength achieved one-point improvement on the Glabellar Lines Scale with the duration of effect lasting 26 weeks, representing a prolonged 6-month performance, the Company reports. The extra-strength glabellar line study is a multicenter, double
- Elsevier Introduces First 3D Human Anatomy Model in Different Skin Toneshttps://practicaldermatology.com/news/elsevier-introduces-first-3d-human-anatomy-model-in-different-skin-tones/2461516/Elsevier is rolling out the newest edition of its 3D anatomy teaching platform, Complete Anatomy 2023, which will feature the most expansive set of skin tone selections ever available in global health education.
- ASA Earns Candid's Platinum Seal of Transparencyhttps://practicaldermatology.com/news/asa-earns-candids-platinum-seal-of-transparency/2461505/The American Skin Association (ASA) recieved Candid's Platinum Seal of Transparency, previously recognized as GuideStar's Platinum Seal of Transparency. Candid collects nonprofit data, and this designation demonstrates that ASA is an organization focused on measuring progr
- Dong-A ST: Phase 3 Trial Shows Therapeutic Equivalence Between Plaque Psoriasis Drug Candidate DMB-3115 and Stelarahttps://practicaldermatology.com/news/dong-a-st-demonstrates-therapeutic-equivalence-between-plaque-psoriasis-drug-candidate-dmb-3115-and-stelara-in-phase-3-trial/2461504/South Korea-based Dong-A ST announced that therapeutic equivalence and safety were established between DMB-3115 and Stelara (ustekinumab; Janssen Biotech), the reference drug, in global phase 3 trials. Stelara is indicated for plaque psoriasis, psoriatic arthritis,